Internal medicine

Guanosine

Disease

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Biology

Prodrug

Outbreak

Virology

In vitro

Coronavirus

2019-20 coronavirus outbreak

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Biochemistry

Medicine

Pharmacology

Antimicrobial Agents and Chemotherapy

The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient treatment.

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 <i>In Vitro</i> and a Promising Oral Antiviral for Treatment of COVID-19

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19